Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Radiat Res. 2017 Feb 16;187(3):298–318. doi: 10.1667/RR4413.1

TABLE 4.

Dexamethasone Support in Rhesus Macaques after WTLI

Treatment course Dexamethasone treated
All NHP
No. treated (n/N) Average mg/kg/day per days alive Average no. of courses Average mg/kg/day per days alive Average no. of courses
A1
 Saline (day 1–28) 18/20 0.029 1.9 0.026 1.8
 AEOL 10150 (day 1–28) 13/20 0.040 2.7 0.026 1.8
 AEOL 10150 (day 1–60) 18/20 0.038 2.8 0.034 2.5
 AEOL 10150 (day 1–28 plus day 60–80) 17/20 0.039 2.5 0.033 2.2
B2
 Saline (day 1–28), survivors 5/5 0.035 2.6 0.035 2.6
 Saline (day 1–28), nonsurvivors 13/15 0.027 1.7 0.023 1.5
 AEOL 10150 (day 1–28), survivors 4/6 0.021 2.0 0.014 1.3
 AEOL 10150 (day 1–28), nonsurvivors   9/14 0.049 3.0 0.031 1.9
 AEOL 10150 (day 1–60), survivors   9/10 0.040 3.1 0.036 2.8
 AEOL 10150 (day 1–60), nonsurvivors   9/10 0.036 2.4 0.033 2.2
 AEOL 10150 (day 1–28 plus day 60–88), survivors 3/4 0.035 3.0 0.026 2.3
 AEOL 10150 (day 1–28 plus day 60–88), nonsurvivors 14/16 0.040 2.4 0.035 2.1

Notes. Dexamethasone was calculated as the mean dosage (mg/kg/day during study days alive) administered for each treatment cohort, control (saline) and AEOL 10150 for day 1–28, day 1–60, and day 1–28 plus day 60–88. Rhesus macaques were administered dexamethasone when the NSRR increased to ≥80 bpm in a prescribed treatment paradigm after 10.74 Gy WTLI.

1

A = Calculations were performed two ways: Considering only the NHP that triggered dexamethasone in each cohort; and considering all NHP in each cohort. The amount of steroid support required was similar across all cohorts regardless of treatment in the study.

2

B = Calculations of dexamethasone support are shown per survivors and nonsurvivors for each cohort, control and schedule-dependent AEOL 10150 treatment.